Pulse Biosciences announced that it has received the Breakthrough Device Designation from the FDA for the company’s Cardiac Surgery System for the ablation of cardiac tissue for the treatment of atrial fibrillation, or AF.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE:
- Pulse Biosciences: Leadership Changes and Stockholder Decisions at Annual Meeting
- Pulse Biosciences Announces SEC-Registered Rights Offering
- Pulse Biosciences Welcomes New President and CEO Barrett
- Pulse Biosciences enhances executive leadership team
- Pulse Biosciences announces 1st procedure with the CellFX nsPFA electrodes